Resumo

ORTIZ-BAUTISTA, Janet Gloria; COLIN-HERNANDEZ, Josefina  e  LEON-ALVAREZ, Erika. Malignant hyperthermia. Rev. mex. anestesiol. [online]. 2023, vol.46, n.1, pp.38-45.  Epub 16-Jun-2023. ISSN 0484-7903.  https://doi.org/10.35366/108621.

Malignant hyperthermia is a rare, life-threatening pharmacogenetic disorder which presents as a hypermetabolic response to volatile anesthetics and depolarizing muscle relaxants in susceptible individuals. This susceptibility is associated with mutations in three genes: RYR1, CACNA1S and STAC3. Can manifest with mild symptoms or as a fulminant crisis, with severe rhabdomyolysis, ventricular fibrillation and acute renal and circulatory failure, therefore the prognosis depends on how soon the diagnosis is suspected and how fast treatment is started. The definitive diagnosis is based on a fresh muscle biopsy sensitivity test and genetic testing. The best way to prevent an event is the early detection of susceptible, as well as have equipment to respond to a crisis in each center where volatile anesthetics are administered and the training of staff. This review synthesizes current clinical and biomedical concepts for detection, prevention, diagnosis and management of malignant hyperthermia.

Palavras-chave : malignant hyperthermia; volatile anesthetics; succinylcholine; RYR1; dantrolene.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )